Biogen Ma Inc.

Sunesis Pharmaceuticals, Inc.

Millennium Pharmaceuticals Limited

Millenium Pharmaceuticals, Inc.

Neurimmune Ag

Joseph Arndt

Deping Wang

Gnanasambandam Kumaravel

Kevin Guckian

Daniel M Scott

Wen-Cherng Lee

Edward Yin-Shiang Lin

Jermaine Thomas

Lei Zhang

Lihong Sun

Timothy Raymond Chan

Daniel A Erlanson

Mia Marie Rushe

Thomas O Cameron

Kurt D Van Vloten

Justin Andrew Caravella

Jan Grimm

Kenneth J Simon

Fabio Montrasio

Ellen Garber Stark

Isin Dalkilic-Liddle

Eric Day

Janine Lisa Ferrant-orgettas

Robert Blake Pepinsky

Ellen Duggan Cahir-mcfarland

Nadia Giselle D'lima

Karl John Mortley Hanf

Daniel Erlanson

Edward Lin

Kurt Van Vloten

Provided are novel dipeptide repeat (DPR) specific antibodies (e.g., human-derived antibodies) as well as synthetic variants and biotechnological derivatives thereof, capable of binding C9orf72 poly-glycine-alanine DPRs, as well as methods and uses related thereto. The antibody of the present invention can be used in pharmaceutical and diagnostic compositions for DPR protein-targeted immunotherapy and diagnostics.

Human-derived anti-(poly-GA) dipeptide repeat (DPR) antibody

The invention relates to anti-VLA-4 antibodies and binding fragments thereof. The invention further includes polynucleotides encoding said antibodies and binding fragments thereof and methods of manufacturing said antibodies and binding fragments thereof. The invention further includes methods of treating patients suffering from multiple sclerosis and/or epilepsy by administration of said antibodies and binding fragments thereof. The invention further includes methods of reducing the susceptibility to scrambling of a recombinant anti-alpha 4 antibody or a binding fragment thereof.

Anti-VLA-4 antibodies having reduced effector function

The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

Heterocyclic compounds useful as PDK1 inhibitors

In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-vims neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-vims. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VP1.

JCV neutralizing antibodies

Growing community of inventors

Peabody, MA, United States of America

Joseph Arndt